Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Receives Average Rating of “Moderate Buy” from Brokerages

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) has received an average rating of “Moderate Buy” from the fourteen research firms that are currently covering the stock, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold recommendation and eleven have assigned a buy recommendation to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $173.07.

JAZZ has been the topic of a number of recent analyst reports. Robert W. Baird lowered their price target on Jazz Pharmaceuticals from $160.00 to $154.00 and set an “outperform” rating on the stock in a research report on Thursday, August 1st. StockNews.com raised Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Thursday, August 1st. Royal Bank of Canada lowered their target price on shares of Jazz Pharmaceuticals from $175.00 to $174.00 and set an “outperform” rating on the stock in a research note on Thursday, August 1st. Needham & Company LLC reissued a “buy” rating and issued a $205.00 target price on shares of Jazz Pharmaceuticals in a research note on Tuesday, September 10th. Finally, Morgan Stanley dropped their target price on Jazz Pharmaceuticals from $160.00 to $150.00 and set an “equal weight” rating for the company in a report on Friday, July 12th.

Jazz Pharmaceuticals Stock Performance

Jazz Pharmaceuticals stock opened at $109.04 on Wednesday. The company has a 50 day moving average price of $111.06 and a 200-day moving average price of $110.69. The company has a debt-to-equity ratio of 1.36, a quick ratio of 2.02 and a current ratio of 2.37. Jazz Pharmaceuticals has a fifty-two week low of $99.06 and a fifty-two week high of $137.38. The company has a market capitalization of $6.88 billion, a PE ratio of 22.48, a P/E/G ratio of 1.36 and a beta of 0.57.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its earnings results on Wednesday, July 31st. The specialty pharmaceutical company reported $4.67 EPS for the quarter, topping analysts’ consensus estimates of $3.80 by $0.87. Jazz Pharmaceuticals had a net margin of 10.10% and a return on equity of 28.65%. The company had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1 billion. As a group, equities analysts forecast that Jazz Pharmaceuticals will post 16.03 earnings per share for the current year.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, SVP Mary Elizabeth Henderson sold 1,410 shares of the firm’s stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $108.30, for a total value of $152,703.00. Following the transaction, the senior vice president now directly owns 14,531 shares of the company’s stock, valued at $1,573,707.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 4.20% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Jazz Pharmaceuticals

Several institutional investors have recently modified their holdings of the company. Sanctuary Advisors LLC acquired a new stake in shares of Jazz Pharmaceuticals in the second quarter valued at $213,000. Point72 Asset Management L.P. grew its stake in shares of Jazz Pharmaceuticals by 20,323.9% in the 2nd quarter. Point72 Asset Management L.P. now owns 182,015 shares of the specialty pharmaceutical company’s stock worth $19,427,000 after purchasing an additional 182,915 shares during the last quarter. Systematic Financial Management LP lifted its stake in Jazz Pharmaceuticals by 5.7% during the second quarter. Systematic Financial Management LP now owns 254,330 shares of the specialty pharmaceutical company’s stock valued at $27,145,000 after purchasing an additional 13,651 shares during the last quarter. Creative Planning boosted its holdings in Jazz Pharmaceuticals by 21.7% during the second quarter. Creative Planning now owns 3,819 shares of the specialty pharmaceutical company’s stock worth $408,000 after buying an additional 680 shares in the last quarter. Finally, Algert Global LLC acquired a new position in Jazz Pharmaceuticals in the second quarter worth approximately $637,000. Institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.